One thing patients must understand before taking the drug: What is pemetinib/pemetinib?

Pemigatinib is a new type of anti-cancer drug that belongs to the class of multikinase inhibitors. It is used to treat a specific type of advanced cholangiocarcinoma (CCA), which usually occurs in the bile duct system. Advanced cholangiocarcinoma is a malignant tumor that is often discovered only when the disease progresses to an advanced stage due to its insidious nature and lack of obvious symptoms. Currently, treatment options for this type of cancer are very limited. However, the emergence of pemetinib has brought new hope to patients with advanced cholangiocarcinoma.

Pemetinib blocks the growth and spread of tumor cells by inhibiting the activity of specific signaling pathways. Specifically, it acts on proteins of the Fibroblast Growth Factor Receptor (FGFR) family, which are overexpressed in tumor cells. By inhibiting these overactive proteins, pemetinib slows the growth of tumors and inhibits their spread to surrounding tissues and organs. Pemetinib can be administered orally, making treatment convenient for patients. Before starting treatment, doctors often perform genetic testing on patients to determine whether their cholangiocarcinoma is related to FGFR gene mutations. For those patients with relevant genetic mutations, pemetinib may be an effective treatment option.

However, like any drug, pemetinib has some side effects. Common side effects include fatigue, nausea, vomiting, diarrhea and other digestive complaints, and may lead to other complaints such as high blood pressure and hand-foot syndrome. Therefore, while using pemetinib, patients need to pay close attention to their physical condition and promptly report any discomfort or abnormal reactions to their doctor.